CD19/BCMA dual-target CAR T cell therapy

CAR T cell therapy targeting CD19 and BCMA · Alexion Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19/BCMA dual-target CAR T cell therapy, covering 2026-03-24 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. [Phase 1, Phase 2]

See pricing